1 year return (CAGR)
-26.29%
Audax Renovables S.A. Exchange (MC, EUR)
ADX.MC
1.03
-0.03 (-2.64%)
UtilitiesUtilities - Renewable
Loading...
3 year return (CAGR)
-3.43%
5 year return (CAGR)
-5.65%
10 year return (CAGR)
8.42%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
459.04M
Price/Sales
0.25
Ent value
1.34B
Price/Book
1.94
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
-1.24%
Trailing P/E
38.43
PEG
-
Forward P/E
9.38
EPS growth
-6.20%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 1.04 |
| Daily high | 1.06 |
| Daily low | 1.03 |
| Daily Volume | 157K |
| All-time high | 9.72 |
| 1y analyst estimate | 2.35 |
| Beta | 1.15 |
| EPS (TTM) | 0.03 |
| Dividend per share | 0.00 |
| Ex-div date | 1 Jul 2026 |
| Next earnings date | 28 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ADX.MC | S&P500 | |
| Current price drop from All-time high | -89.38% | -1.94% |
| Highest price drop | -97.22% | -56.47% |
| Date of highest drop | 25 Apr 2013 | 9 Mar 2009 |
| Avg drop from high | -80.35% | -10.65% |
| Avg time to new high | 71 days | 12 days |
| Max time to new high | 4922 days | 1805 days |
News
Investing.com -- Melexis NV (EBR:MLXS) on Wednesday reported third quarter revenue of €224 million, matching analyst consensus estimates of €224 million, as the semiconductor company navigates normali...
October 28, 2026
Novartis reported Q3 2026 sales of US$14.52b and net income of US$1.20b, and then raised its full year core operating income outlook after margin expansion and strong contributions from priority medic...
October 28, 2026
Intrum’s latest analyst update centers on a lower fair value, with the price target reduced from SEK 5.47 to SEK 4.63, a cut of about 15% in the target valuation. Analysts link this move to refreshed ...
October 28, 2026
Novartis (NYSE:NVS) reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core oper...
October 27, 2026
Sigma Foods, S.A.B. de C.V. (BMV: SIGMAFA) ("SIGMA FOODS") announced today its unaudited results for the third quarter of 2026 ("3Q26"). All figures have been prepared in accordance with International...
October 27, 2026
Novartis stock rose slightly early Tuesday on strong third-quarter income, but the second biggest moneymaker fell short.
October 27, 2026
Priority brands offset generic erosion as margin expands and pipeline advances.
October 27, 2026
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
October 27, 2026
Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
October 27, 2026
